
Claims

1. The use of a compound of the formula (I)




(I)

in which

R^1 and R^2 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycle which may contain a further heteroatom from the group consisting of N, O and S, where the 4- to 7-membered heterocycle may be substituted by 1 to 2 substituents independently of one another selected from the group consisting of fluorine, trifluoromethyl, (C_1-C_4)-alkyl, trifluoromethoxy and (C_1-C_4)-alkoxy,

R^3 represents hydrogen or a group of the formula



where

\# represents the point of attachment to the oxygen atom,

R^4 represents hydrogen, methyl, propan-2-yl, propan-1-yl, 2-methylpropan-1-yl, 1-methylpropan-1-yl, butan-1-yl, *tert*-butyl, phenyl, benzyl, p-hydroxybenzyl, indol-3-ylmethyl, imidazol-4-ylmethyl, hydroxymethyl, 2-hydroxyethyl, 1-hydroxyethyl, mercaptomethyl, methylthiomethyl, 2-mercaptoethyl, 2-methylthioethyl, carbamoylmethyl, 2-carbamoylethyl, carboxymethyl, 2-carboxyethyl, 4-aminobutan-1-yl, 4-amino-3-hydroxybutan-1-yl, 3-aminopropan-1-yl, 2-aminoethyl, aminomethyl, 3-guanidinopropan-1-yl or 3-ureidopropan-1-yl,

R^5 represents hydrogen,

R^6 represents hydrogen,

R^7 represents hydrogen,

R^8 represents hydrogen, methyl, propan-2-yl, propan-1-yl, 2-methylpropan-1-yl, 1-methylpropan-1-yl, butan-1-yl, *tert*-butyl, phenyl, benzyl, p-hydroxybenzyl, indol-3-ylmethyl, imidazol-4-ylmethyl, hydroxymethyl, 2-hydroxyethyl, 1-hydroxyethyl, mercaptomethyl, methylthiomethyl, 2-mercaptoethyl, 2-methylthioethyl, carbamoylmethyl, 2-carbamoylethyl, carboxymethyl, 2-carboxyethyl, 4-aminobutan-1-yl, 4-amino-3-

hydroxybutan-1-yl, 3-aminopropan-1-yl, 2-aminoethyl, aminomethyl, 3-guanidinopropan-1-yl or 3-ureidopropan-1-yl,

R^9 represents hydrogen,

R^{10} represents hydrogen or methyl,

R^{11} represents hydrogen, methyl, propan-2-yl, propan-1-yl, 2-methylpropan-1-yl, 1-methylpropan-1-yl, butan-1-yl, *tert*-butyl, phenyl, benzyl, p-hydroxybenzyl, indol-3-ylmethyl, imidazol-4-ylmethyl, hydroxymethyl, 2-hydroxyethyl, 1-hydroxyethyl, mercaptomethyl, methylthiomethyl, 2-mercaptoethyl, 2-methylthioethyl, carbamoylmethyl, 2-carbamoylethyl, carboxymethyl, 2-carboxyethyl, 4-aminobutan-1-yl, 4-amino-3-hydroxybutan-1-yl, 3-aminopropan-1-yl, 2-aminoethyl, aminomethyl, 3-guanidinopropan-1-yl or 3-ureidopropan-1-yl,

R^{12} represents hydrogen,

R^{13} represents hydrogen,


R^{14} represents hydrogen,

and the N-oxides, salts, solvates, salts of the N-oxides and solvates of the N-oxides or salts thereof in the manufacture of a medicament for the treatment and/or prevention of acute and/or chronic renal insufficiency.

2. The use of a compound of the formula (I) according to Claim 1 in which

R^1 and R^2 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycle which may contain a further heteroatom from the group consisting of N, O and S, where the 4- to 7-membered heterocycle may be substituted by 1 to 2 substituents independently of one another selected from the group consisting of fluorine, trifluoromethyl, $(C_1$-$C_4)$-alkyl, trifluoromethoxy and $(C_1$-$C_4)$-alkoxy,

R^3 represents hydrogen or a group of the formula



where

\# represents the point of attachment to the oxygen atom,

R^4 represents hydrogen, methyl, propan-2-yl, 2-methylpropan-1-yl, benzyl, imidazol-4-ylmethyl, hydroxymethyl, 1-hydroxyethyl, 4-aminobutan-1-yl, 3-aminopropan-1-yl, 2-aminoethyl, aminomethyl or 3-guanidinopropan-1-yl,

R^5 represents hydrogen,

R^6 represents hydrogen,

R^7 represents hydrogen,

R^8 represents hydrogen, methyl, propan-2-yl, 2-methylpropan-1-yl, benzyl, imidazol-4-ylmethyl, hydroxymethyl, 1-hydroxyethyl, 4-aminobutan-1-yl, 3-aminopropan-1-yl, 2-aminoethyl, aminomethyl or 3-guanidinopropan-1-yl,

R^9 represents hydrogen,

R^{10} represents hydrogen or methyl,

R^{11} represents hydrogen, methyl, propan-2-yl, 2-methylpropan-1-yl, benzyl, imidazol-4-ylmethyl, hydroxymethyl, 1-hydroxyethyl, 4-aminobutan-1-yl, 3-aminopropan-1-yl, 2-aminoethyl, aminomethyl or 3-guanidinopropan-1-yl,

R^{12} represents hydrogen,


R^{13} represents hydrogen,

and the N-oxides, salts, solvates, salts of the N-oxides and solvates of the N-oxides or salts thereof in the manufacture of a medicament for the treatment and/or prevention of acute and/or chronic renal insufficiency.

3. The use of a compound of the formula (I) according to Claim 1 in which

R^1 and R^2 together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocycle which may contain a further heteroatom from the group consisting of N, O and S, where the 4- to 6-membered heterocycle may be substituted by 1 to 2 substituents independently of one another selected from the group consisting of fluorine, trifluoromethyl, $(C_1$-$C_4)$-alkyl, trifluoromethoxy, methoxy and ethoxy,

R^3 represents hydrogen or a group of the formula



where

\# represents the point of attachment to the oxygen atom,

R^4 represents 3-aminopropan-1-yl,

R^5 represents hydrogen,

R^6 represents hydrogen,

R^7 represents hydrogen,

R^8 represents methyl,

R^9 represents hydrogen,

R^{10} represents hydrogen,

R^{11} represents methyl, 2-aminoeth-1-yl, 4-aminobut-1-yl, 3-guanidinopropan-1-yl or imidazol-4-ylmethyl,

R^{12} represents hydrogen,

R^{13} represents hydrogen,



R^{14} represents hydrogen,

and the N-oxides, salts, solvates, salts of the N-oxides and solvates of the N-oxides or salts thereof in the manufacture of a medicament for the treatment and/or prevention of acute and/or chronic renal insufficiency.

4. The use of a compound of the formula (I) according to Claim 1 or 3 in which

R^1 and R^2 together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocycle which may contain a further heteroatom from the group consisting of N, O and S,

R^3 represents hydrogen or a group of the formula


or


where

represents the point of attachment to the oxygen atom,

R^4 represents 3-aminopropan-1-yl,

R^5 represents hydrogen,

R^6 represents hydrogen,

R^7 represents hydrogen,

R^8 represents methyl,

R^9 represents hydrogen,

R^{10} represents hydrogen,

R^{11} represents methyl, 2-aminoeth-1-yl, 4-aminobut-1-yl, 3-guanidinopropan-1-yl or imidazol-4-ylmethyl,

R^{12} represents hydrogen,

R^{13} represents hydrogen,

R^{14} represents hydrogen,



and the N-oxides, salts, solvates, salts of the N-oxides and solvates of the N-oxides or salts thereof in the manufacture of a medicament for the treatment and/or prevention of acute and/or chronic renal insufficiency.

5. The use of a compound of the formula (I) according to one or more of Claims 1, 3 or 4 in which

R^1 and R^2 together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl or piperidinyl ring,

where the azetidinyl ring may be substituted by a methoxy substituent,

R^3 represents hydrogen or a group of the formula


or


where

represents the point of attachment to the oxygen atom,

R^4 represents 3-aminopropan-1-yl,

R^5 represents hydrogen,

R^6 represents hydrogen,

R^7 represents hydrogen,

R^8 represents methyl,

R^9 represents hydrogen,

R^{10} represents hydrogen,

R^{11} represents methyl, 2-aminoeth-1-yl, 4-aminobut-1-yl, 3-guanidinopropan-1-yl or imidazol-4-ylmethyl,

R^{12} represents hydrogen,

R^{13} represents hydrogen,

R^{14} represents hydrogen,

and the N-oxides, salts, solvates, salts of the N-oxides and solvates of the N-oxides or salts thereof in the manufacture of a medicament for the treatment and/or prevention of acute and/or chronic renal insufficiency.

6. The use of a compound of the formula (I) according to one or more of Claims 1 to 5 in which

R^3 represents hydrogen,

and the N-oxides, salts, solvates, salts of the N-oxides and solvates of the N-oxides or salts thereof in the manufacture of a medicament for the treatment and/or prevention of acute and/or chronic renal insufficiency.

7. The use of a compound of the formula (I) according to one or more of Claims 1, 2, 3 or 4, selected from the group below:


2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulphanyl)-4-[4-(2-hydroxyethoxy)phenyl]-6-(3-methoxyazetidin-1-yl)pyridine-3,5-dicarbonitrile

2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulphanyl)-4-[4-(2-hydroxyethoxy)phenyl]-6-(pyrrolidin-1-yl)pyridine-3,5-dicarbonitrile

2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulphanyl)-4-[4-(2-hydroxyethoxy)phenyl]-6-(piperidin-1-yl)pyridine-3,5-dicarbonitrile,

and the N-oxides, salts, solvates, salts of the N-oxides and solvates of the N-oxides or salts thereof in the manufacture of a medicament for the treatment and/or prevention of acute and/or chronic renal insufficiency.

8. The use of a compound of the formula



2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-4-[4-(2-hydroxyethoxy)phenyl]-6-(pyrrolidin-1-yl)pyridine-3,5-dicarbonitrile

and the N-oxides, salts, solvates, salts of the N-oxides and solvates of the N-oxides or salts thereof

in the manufacture of a medicament for the treatment and/or prevention of acute and/or chronic renal insufficiency.

9. Use of the compound of the formula (I) according to one or more of Claims 1 to 8 in the manufacture of a medicament for the treatment and/or prevention of acute and/or chronic renal insufficiency in combination with coronary heart disease, acute coronary syndrome, angina pectoris, heart failure, myocardial infarction and atrial fibrillation.

10. Use of the compound of the formula (I) according to one or more of Claims 1 to 8 in the manufacture of a medicament for the treatment and/or prevention of acute and/or chronic renal insufficiency in combination with diabetes, metabolic syndrome and dyslipidaemias.